Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) closed the day trading at $14.23 down -3.33% from the previous closing price of $14.72. In other words, the price has decreased by -$3.33 from its previous closing price. On the day, 0.76 million shares were traded. DCPH stock price reached its highest trading level at $14.91 during the session, while it also had its lowest trading level at $14.19.
Ratios:
For a better understanding of DCPH, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.59 and its Current Ratio is at 3.80. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On October 30, 2023, Piper Sandler Upgraded its rating to Overweight which previously was Neutral but kept the price unchanged to $23.
Stifel Upgraded its Hold to Buy on August 10, 2023, whereas the target price for the stock was revised from $14 to $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 16 ’24 when Kelly Thomas Patrick sold 3,010 shares for $15.62 per share. The transaction valued at 47,009 led to the insider holds 80,350 shares of the business.
Sherman Matthew L sold 2,615 shares of DCPH for $40,840 on Feb 16 ’24. The EVP & Chief Medical Officer now owns 108,739 shares after completing the transaction at $15.62 per share. On Feb 16 ’24, another insider, Pitman Jama, who serves as the SVP, Chief Development Officer of the company, sold 2,267 shares for $15.62 each. As a result, the insider received 35,405 and left with 68,031 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DCPH now has a Market Capitalization of 1149785344 and an Enterprise Value of 869447872. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.04 while its Price-to-Book (P/B) ratio in mrq is 3.26. Its current Enterprise Value per Revenue stands at 5.322 whereas that against EBITDA is -4.163.
Stock Price History:
Over the past 52 weeks, DCPH has reached a high of $17.73, while it has fallen to a 52-week low of $9.90. The 50-Day Moving Average of the stock is -9.05%, while the 200-Day Moving Average is calculated to be 1.29%.
Shares Statistics:
Over the past 3-months, DCPH traded about 534.15K shares per day on average, while over the past 10 days, DCPH traded about 427870 shares per day. A total of 80.50M shares are outstanding, with a floating share count of 49.41M. Insiders hold about 38.85% of the company’s shares, while institutions hold 63.84% stake in the company. Shares short for DCPH as of 1711584000 were 6059264 with a Short Ratio of 11.34, compared to 1709164800 on 5509039. Therefore, it implies a Short% of Shares Outstanding of 6059264 and a Short% of Float of 9.99.
Earnings Estimates
The dynamic stock of Deciphera Pharmaceuticals Inc (DCPH) is currently being evaluated by a team of Delcath Systems, Inc. analysts, each contributing to its current rating.
